Tamoxifen: A personal retrospective

Lancet Oncology

Volumn 1, Issue 1, 2000, Pages 43-49

  Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; FEMALE; HISTORY; HUMAN;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0034286302     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00009-7     Document Type: Note

References (58)

1. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Eighth Cain memorial award lecture. Cancer Res. 50:1990;4177-4189.
2. Official literature on new drugs: Clomiphene citrate (Clomid). Clin Pharmacol Ther. 8:1967;891-897.
3. Herbst AL, Griffiths CT, Kistner RW. Clomiphene citrate (NSC-35770) in disseminated mammary carcinoma. Cancer Chemother Rep. 43:1964;39-41.
4. Harper MJ, Walpole AL. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil. 13:1967;101-119.
5. El-Sheikha Z, Klopper A, Beck JS. Treatment of menometrorrhagia with antioestrogen. Clin Endocrinol. 1:1972;275-282.
6. Williamson JG, Ellis JD. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonwealth. 80:1973;844-847.
7. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 25:1984;127-205.
8. Walpole AL. Nonsteroidal drugs in relation to ovulation and implantation. J Reprod Fertil. Suppl 4:1968;3-14.
9. Walpole AL, Paterson E. Synthetic oestrogens in mammary cancer. Lancet. ii:1949;783-789.
10. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 18:1962;387-414.
11. Jensen EV, Block GE, Smith S, et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr. 34:1971;55-70.
12. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46, 474. Br J Cancer. 25:1971;270-275.
13. Jordan VC, Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer. 11:1975;205-206.
14. Jordan VC. Antitumour activity of the anti-oestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem. 5:1974;354.
15. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 12:1976;419-424.
16. Powell-Jones W, Davies P, Griffiths K. Influence of anti-oestrogens on specific binding of [3H] oestradiol by nuclei from rat mammary tumours. J Endocrinol. 66:1975;437-438.
17. 3H] oestradiol by cytosol of rat mammary tumors and human breast carcinomata. Biochem J. 150:1975;71-75.
18. Nicholson RI, Golder MP. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer. 11:1975;571-579.
19. Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. BMJ. 1:1973;13-14.
20. Jordan VC. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep. 60:1976;1409-1419.
21. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent anti-oestrogenic activity. J Endocrinol. 75:1977;305-316.
22. Jordan VC, Dix CJ, Allen KE. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: Salmon SE, Jones SE (Eds). Adjuvant therapy of cancer. New York: Grune & Stratton, Inc., 1979: 19-26.
23. Jordan VC, Allen KE, Dix CJ. Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep. 64:1980;745-759.
24. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
25. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388.
26. Kiang DT, Kennedy BJ. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med. 87:1977;687-690.
27. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. i:1983;257-261.
28. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. ii:1987;171-175.
29. Wallgren A, Baral E, Castensen J, et al. Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones S, Salmon S, (Eds). Adjuvant therapy of breast cancer IV. New York: Grune and Stratton, 1984: 331-38.
30. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol. 9:1991;1740-1748.
31. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 88:1996;1543-1549.
32. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. i:1983;227-241.
33. Tormey DC, Jordan VC. Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat. 4:1984;297-302.
34. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst. 88:1996;1828-1833.
35. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 320:1989;479-484.
36. Fisher B, Brown A, Wolmark N, et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 106:1987;649-654.
37. Baum M, Brinkley DM, Dossett JA, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer [letter]. Lancet. ii:1983;450.
38. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. ii:1985;282.
39. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 6:2000;2028-2036.
40. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer. 27:1936;217-225.
41. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 14:1996;78-84.
42. Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat. 10:1987;31-35.
43. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326:1992;852-856.
44. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 115:1991;860-864.
45. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 303:1991;435-437.
46. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 89:1997;776-782.
47. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
48. Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. i:1989;117-120.
49. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst. 91:1999;1654-1662.
50. White IN. The tamoxifen dilemma. Carcinogenesis. 20:1999;1153-1160.
51. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 353:1999;1993-2000.
52. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101.
53. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 352:1998;93-97.
54. Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. ASCO. 2a:1998;3.
55. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double blind, randomized trials in 12,000 postmenopausal women (abstract). ASCO. 122a:1998;466.
56. Jordan VC, Morrow M. Raloxifene as a multifunctional medicine? BMJ. 319:1999;331-332.
57. Jordan VC. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat. 11:1988;197-209.
58. Jordan VC, Glusman JE, Eckert S, et al. Raloxifene reducesincident primary breast cancer: integrated data from multicenter double blind placebo controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat. 50:1998;227.